Pareyn, M. et al. Leishmaniasis. Nat. Rev. Dis. Primers 11, 81 (2025). This is a contemporary review of the clinico-epidemiological features of leishmaniasis, immunobiology, diagnostics and therapeutic interventions.
Bailey, F. et al. Cutaneous leishmaniasis and co-morbid major depressive disorder: a systematic review with burden estimates. PLoS Negl. Trop. Dis. 13, e0007092 (2019).
Leishmaniasis key facts. World Health Organisation https://www.who.int/news-room/fact-sheets/detail/leishmaniasis (2023).
Alvar, J., Beca-Martinez, M. T., Argaw, D., Jain, S. & Aagaard-Hansen, J. Social determinants of visceral leishmaniasis elimination in eastern Africa. BMJ Glob. Health 8, e012638 (2023).
Alvar, J., den Boer, M. & Dagne, D. A. Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action. Lancet Glob. Health 9, e1763–e1769 (2021).
Dahl, E. H. et al. Control of visceral leishmaniasis in East Africa: fragile progress, new threats. BMJ Glob. Health 6, e006835 (2021).
WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. World Health Organisation https://www.who.int/publications/i/item/9789240048294 (2022).
Costa, C. H. N., Chang, K. P., Costa, D. L. & Cunha, F. V. M. From infection to death: an overview of the pathogenesis of visceral leishmaniasis. Pathogens 12, 969 (2023).
Gasim, S. et al. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin. Exp. Immunol. 111, 64–69 (1998).
Kirstein, O. D. et al. Minimally invasive microbiopsies: a novel sampling method for identifying asymptomatic, potentially infectious carriers of Leishmania donovani. Int. J. Parasitol. 47, 609–616 (2017).
Cloots, K. et al. Assessing L. donovani skin parasite load: a proof of concept study of a microbiopsy device in an Indian setting. Front. Cell Infect. Microbiol. 11, 645121 (2021).
Arumugam, S., Scorza, B. M. & Petersen, C. Visceral leishmaniasis and the skin: dermal parasite transmission to sand flies. Pathogens 11, 610 (2022).
Sengupta, R., Roy, M., Dey, N. S., Kaye, P. M. & Chatterjee, M. Immune dysregulation and inflammation causing hypopigmentation in post kala-azar dermal leishmaniasis: partners in crime? Trends Parasitol. 39, 822–836 (2023).
Singh, O. P. & Sundar, S. Visceral leishmaniasis elimination in India: progress and the road ahead. Expert Rev. Anti-infect. Ther. 20, 1381–1388 (2022).
Chalghaf, B. et al. Ecological niche modeling predicting the potential distribution of Leishmania vectors in the Mediterranean basin: impact of climate change. Parasit. Vectors 11, 461 (2018).
Kipp, E. J. et al. An atypical case of autochthonous cutaneous leishmaniasis associated with naturally infected phlebotomine sand flies in Texas, United States. Am. J. Trop. Med. Hyg. 103, 1496–1501 (2020).
McBride, W. J. Chemoprophylaxis of tropical infectious diseases. Pharmaceuticals 3, 1561–1575 (2010).
Singh, V. K. et al. Advancing treatment for leishmaniasis: from overcoming challenges to embracing therapeutic innovations. ACS Infect. Dis. 11, 47–68 (2025).
Marou, V. et al. The impact of conflict on infectious disease: a systematic literature review. Confl. Health 18, 27 (2024).
Catta-Preta, C. M. C., Ghosh, K., Sacks, D. L. & Ferreira, T. R. Single-cell atlas of Leishmania development in sandflies reveals the heterogeneity of transmitted parasites and their role in infection. Proc. Natl Acad. Sci. USA 121, e2406776121 (2024). This is a reassessment of the nature of infectious forms of Leishmania.
DeSouza-Vieira, T. et al. Heme oxygenase-1 induction by blood-feeding arthropods controls skin inflammation and promotes disease tolerance. Cell Rep. 33, 108317 (2020).
Dey, R. et al. Gut microbes egested during bites of infected sand flies augment severity of leishmaniasis via inflammasome-derived IL-1β. Cell Host Microbe 23, 134–143 e136 (2018).
Peters, N. C. et al. In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 321, 970–974 (2008).
Bogdan, C. et al. The immunomicrotope of Leishmania control and persistence. Trends Parasitol. 40, 788–804 (2024). This is an excellent guide to the microenvironmental factors shaping immunity in leishmaniasis.
Kaye, P. & Scott, P. Leishmaniasis: complexity at the host–pathogen interface. Nat. Rev. Microbiol. 9, 604–615 (2011).
Vivier, E. et al. Innate lymphoid cells: 10 years on. Cell 174, 1054–1066 (2018).
Korchagina, A. A., Koroleva, E. & Tumanov, A. V. Innate lymphoid cells in response to intracellular pathogens: protection versus immunopathology. Front. Cell Infect. Microbiol. 11, 775554 (2021).
Prajeeth, C. K., Haeberlein, S., Sebald, H., Schleicher, U. & Bogdan, C. Leishmania-infected macrophages are targets of NK cell-derived cytokines but not of NK cell cytotoxicity. Infect. Immun. 79, 2699–2708 (2011).
Alizadeh, Z. et al. Unraveling the role of natural killer cells in leishmaniasis. Int. Immunopharmacol. 114, 109596 (2023).
Caneda-Guzman, I. C. et al. NK cell activity differs between patients with localized and diffuse cutaneous leishmaniasis infected with Leishmania mexicana: a comparative study of TLRs and cytokines. PLoS ONE 9, e112410 (2014).
Fantecelle, C. H. et al. Transcriptomic landscape of skin lesions in cutaneous leishmaniasis reveals a strong CD8+ T cell immunosenescence signature linked to immunopathology. Immunology 164, 754–765 (2021). This was the first study to implicate senescent T cells in leishmaniasis immunopathology.
Pellicci, D. G., Koay, H. F. & Berzins, S. P. Thymic development of unconventional T cells: how NKT cells, MAIT cells and γδ T cells emerge. Nat. Rev. Immunol. 20, 756–770 (2020).
Dhodapkar, M. V. & Kumar, V. Type II NKT cells and their emerging role in health and disease. J. Immunol. 198, 1015–1021 (2017).
Kumari, S. et al. Leishmania donovani mediated higher expression of CCL4 induces differential accumulation of CD4+CD56+NKT and CD8+CD56+NKT cells at infection site. Cytokine 110, 306–315 (2018).
Kumari, S. et al. CD8dim but not CD8bright cells positive to CD56 dominantly express KIR and are cytotoxic during visceral leishmaniasis. Hum. Immunol. 79, 616–620 (2018).
Ferraz, R. et al. CD3+CD4–CD8– (double negative) T lymphocytes and NKT cells as the main cytotoxic-related-CD107a+ cells in lesions of cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Parasit. Vectors 10, 219 (2017).
Mattner, J., Donhauser, N., Werner-Felmayer, G. & Bogdan, C. NKT cells mediate organ-specific resistance against Leishmania major infection. Microbes Infect. 8, 354–362 (2006).
Belo, R. et al. Leishmania infantum exoproducts inhibit human invariant NKT cell expansion and activation. Front. Immunol. 8, 710 (2017).
Amprey, J. L. et al. A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J. Exp. Med. 200, 895–904 (2004).
Castillo-Gonzalez, R., Cibrian, D. & Sanchez-Madrid, F. Dissecting the complexity of γδ T-cell subsets in skin homeostasis, inflammation, and malignancy. J. Allergy Clin. Immunol. 147, 2030–2042 (2021).
Modlin, R. L. et al. Lymphocytes bearing antigen-specific γδ T-cell receptors accumulate in human infectious disease lesions. Nature 339, 544–548 (1989). This is a landmark paper identifying γδ T cells in Leishmania cutaneous granulomas.
Alaibac, M. et al. Molecular analysis of the γδ T-cell receptor repertoire in normal human skin and in Oriental cutaneous leishmaniasis. Exp. Dermatol. 2, 106–112 (1993).
Uyemura, K. et al. Microanatomic clonality of γδ T cells in human leishmaniasis lesions. J. Immunol. 148, 1205–1211 (1992).
Antonelli, L. R. et al. Disparate immunoregulatory potentials for double-negative (CD4– CD8–) αβ and γδ T cells from human patients with cutaneous leishmaniasis. Infect. Immun. 74, 6317–6323 (2006).
Lagler, H. et al. Cellular profile of cytokine production in a patient with visceral leishmaniasis: γδ+ T cells express both type 1 cytokines and interleukin-10. Scand. J. Immunol. 57, 291–295 (2003).
Russo, D. M. et al. Antigen-reactive γδ T cells in human leishmaniasis. J. Immunol. 151, 3712–3718 (1993).
Sheel, M. et al. IL-17A-producing γδ T cells suppress early control of parasite growth by monocytes in the liver. J. Immunol. 195, 5707–5717 (2015).
Hu, Y. et al. γδ T cells: origin and fate, subsets, diseases and immunotherapy. Signal. Transduct. Target. Ther. 8, 434 (2023).
Rosat, J. P., MacDonald, H. R. & Louis, J. A. A role for γδ+ T cells during experimental infection of mice with Leishmania major. J. Immunol. 150, 550–555 (1993).
McWilliam, H. E. G. & Villadangos, J. A. MR1 antigen presentation to MAIT cells and other MR1-restricted T cells. Nat. Rev. Immunol. 24, 178–192 (2024).
Borges-Fernandes, L. O. et al. MR1 blockade drives differential impact on integrative signatures based on circuits of circulating immune cells and soluble mediators in visceral leishmaniasis. Front. Immunol. 15, 1373498 (2024). This is a rare functional study implicating MR1T in visceral leishmaniasis.
Moreira, M. L. et al. The role of mucosal-associated invariant T cells in visceral leishmaniasis. Front. Immunol. 13, 926446 (2022).
Figueiredo, A. B. et al. Circulating soluble factors and T-cell subsets as immunological predictors of therapy response in human cutaneous leishmaniasis. J. Infect. Dis. 232, 236–246 (2025).
Galvao-Castro, B. et al. Polyclonal B cell activation, circulating immune complexes and autoimmunity in human American visceral leishmaniasis. Clin. Exp. Immunol. 56, 58–66 (1984).
Ghose, A. C., Haldar, J. P., Pal, S. C., Mishra, B. P. & Mishra, K. K. Serological investigations on Indian kala-azar. Clin. Exp. Immunol. 40, 318–326 (1980).
Evans, T. G. et al. Evaluation of antibody responses in American visceral leishmaniasis by ELISA and immunoblot. Mem. Inst. Oswaldo Cruz 84, 157–166 (1989).
Silva-O’Hare, J. et al. Disruption of splenic lymphoid tissue and plasmacytosis in canine visceral leishmaniasis: changes in homing and survival of plasma cells. PLoS ONE 11, e0156733 (2016).
Spada, E. et al. Feline Leishmania spp. infection in a non-endemic area of northern Italy. Animals 10, 817 (2020).
Rodrigues, V. et al. Abortive T follicular helper development is associated with a defective humoral response in Leishmania infantum-infected macaques. PLoS Pathog. 10, e1004096 (2014).
Campos-Neto, A. & Bunn-Moreno, M. M. Polyclonal B cell activation in hamsters infected with parasites of the genus Leishmania. Infect. Immun. 38, 871–876 (1982).
Silva-Barrios, S. et al. Innate immune B cell activation by Leishmania donovani exacerbates disease and mediates hypergammaglobulinemia. Cell Rep. 15, 2427–2437 (2016). This paper demonstrates the crucial role of IFN-I in sustaining hypergammaglobulinaemia in experimental visceral leishmaniasis.
Deak, E. et al. Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation. Eur. J. Immunol. 40, 1355–1368 (2010).
Hasker, E. et al. Strong association between serological status and probability of progression to clinical visceral leishmaniasis in prospective cohort studies in India and Nepal. PLoS Negl. Trop. Dis. 8, e2657 (2014).
de Carvalho, C. A., Hiramoto, R. M., Meireles, L. R. & de Andrade, H. F. Jr Understanding hypergammaglobulinemia in experimental or natural visceral leishmaniasis. Parasite Immunol. 46, e13021 (2024).
Reis, A. B. et al. Systemic and compartmentalized immune response in canine visceral leishmaniasis. Vet. Immunol. Immunopathol. 128, 87–95 (2009).
Chandra, H., Chandra, S. & Kaushik, R. M. Visceral leishmaniasis with associated common, uncommon, and atypical morphological features on bone marrow aspirate cytology in nonendemic region. J. Trop. Med. 2013, 861032 (2013).
De Cerqueira, M. A. F., Pinheiro, A. M. R., Costa, D. L. & Costa, C. H. N. Association between clinical outcomes, peripheral blood and cytomorphologic features of bone marrow in visceral leishmaniasis. Hematol. Transfus. Cell Ther. 46 (suppl. 6), S41–S47 (2024).
Singh, B., Singh, O. P., Singh, N., Singh, S. S. & Sundar, S. Abnormal B-cell subset and blimp-1-mediated humoral responses associated with visceral leishmaniasis pathogenesis. Am. J. Trop. Med. Hyg. 100, 816–821 (2019). This paper is a comprehensive analysis of B cell subsets in the blood and splenic aspirates of visceral leishmaniasis patients.
Minnich, M. et al. Multifunctional role of the transcription factor Blimp-1 in coordinating plasma cell differentiation. Nat. Immunol. 17, 331–343 (2016).
Schweighoffer, E. & Tybulewicz, V. L. J. BAFF signaling in health and disease. Curr. Opin. Immunol. 71, 124–131 (2021).
Goto, Y., Omachi, S., Sanjoba, C. & Matsumoto, Y. Elevation of serum B-cell activating factor levels during visceral leishmaniasis. Am. J. Trop. Med. Hyg. 91, 912–914 (2014).
Mackay, F. & Browning, J. L. BAFF: a fundamental survival factor for B cells. Nat. Rev. Immunol. 2, 465–475 (2002).
Omachi, S. et al. B-cell activating factor deficiency suppresses splenomegaly during Leishmania donovani infection. Biochem. Biophys. Res. Commun. 489, 528–533 (2017).
Parodi, C. et al. B-cell profile, B-cell activating factor concentration and IgG levels in human cutaneous and mucosal leishmaniasis. Parasite Immunol. 42, e12759 (2020).
Zhao, E. J., Cheng, C. V., Mattman, A. & Chen, L. Y. C. Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management. Lancet Haematol. 8, e365–e375 (2021).
Hirano, T. & Kishimoto, T. Interleukin 6 and plasma cell neoplasias. Prog. Growth Factor. Res. 1, 133–142 (1989).
Kishimoto, T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res. Ther. 8 (suppl. 2), S2 (2006).
Aliyu, M. et al. Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach. Int. Immunopharmacol. 111, 109130 (2022).
Dos Santos, P. L. et al. The severity of visceral leishmaniasis correlates with elevated levels of serum IL-6, IL-27 and sCD14. PLoS Negl. Trop. Dis. 10, e0004375 (2016).
Ansari, N. A., Ramesh, V. & Salotra, P. Interferon (IFN)-γ, tumor necrosis factor-α, interleukin-6, and IFN-γ receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis. J. Infect. Dis. 194, 958–965 (2006).
Kumar, R. et al. Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of visceral leishmaniasis. Cell Rep. 30, 2512–2525.e2519 (2020).
Silva-Barrios, S. & Stager, S. Hypergammaglobulinemia sustains the development of regulatory responses during chronic Leishmania donovani infection in mice. Eur. J. Immunol. 49, 1082–1091 (2019).
Stogerer, T. et al. Leishmania donovani exploits tunneling nanotubes for dissemination and propagation of B cell activation. Microbiol. Spectr. 11, e0509622 (2023).
Bankoti, R., Gupta, K., Levchenko, A. & Stager, S. Marginal zone B cells regulate antigen-specific T cell responses during infection. J. Immunol. 188, 3961–3971 (2012).
Dirkx, L. et al. Effect of Leishmania infantum infection on B cell lymphopoiesis and memory in the bone marrow and spleen. FASEB J. 38, e23893 (2024).
Andreani, G. et al. Leishmania infantum amastigotes trigger a subpopulation of human B cells with an immunoregulatory phenotype. PLoS Negl. Trop. Dis. 9, e0003543 (2015).
Cabral, S. M. et al. A Leishmania infantum cytosolic tryparedoxin activates B cells to secrete interleukin-10 and specific immunoglobulin. Immunology 123, 555–565 (2008).
Cordeiro-Da-Silva, A., Borges, M. C., Guilvard, E. & Ouaissi, A. Dual role of the Leishmania major ribosomal protein S3a homologue in regulation of T- and B-cell activation. Infect. Immun. 69, 6588–6596 (2001).
Silvestre, R., Cordeiro-da-Silva, A., Tavares, J., Sereno, D. & Ouaissi, A. Leishmania cytosolic silent information regulatory protein 2 deacetylase induces murine B-cell differentiation and in vivo production of specific antibodies. Immunology 119, 529–540 (2006).
Pearson, R. D. et al. Circulating immune complexes and rheumatoid factors in visceral leishmaniasis. J. Infect. Dis. 147, 1102 (1983).
Pisetsky, D. S. Pathogenesis of autoimmune disease. Nat. Rev. Nephrol. 19, 509–524 (2023).
Nimmerjahn, F. & Ravetch, J. V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310, 1510–1512 (2005).
Pincetic, A. et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15, 707–716 (2014).
Zauner, G. et al. Glycoproteomic analysis of antibodies. Mol. Cell Proteom. 12, 856–865 (2013).
Malhotra, R. et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1, 237–243 (1995).
Gardinassi, L. G. et al. Clinical severity of visceral leishmaniasis is associated with changes in immunoglobulin G Fc N-glycosylation. mBio 5, e01844 (2014). Thorough investigation of FcγR N-glycosylation in symptomatic and asymptomatic individuals.
Miles, S. A., Conrad, S. M., Alves, R. G., Jeronimo, S. M. & Mosser, D. M. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J. Exp. Med. 201, 747–754 (2005). This paper demonstrates that anti-Leishmania IgG induces IL-10 in macrophages in mice.
Gonzaga, W. F., Xavier, V., Vivanco, B. C., Lopes, J. D. & Xander, P. B-1 cells contribute to susceptibility in experimental infection with Leishmania (Leishmania) chagasi. Parasitology 142, 1506–1515 (2015).
Schaut, R. G. et al. Regulatory IgDhi B cells suppress T cell function via IL-10 and PD-L1 during progressive visceral leishmaniasis. J. Immunol. 196, 4100–4109 (2016).
Sengupta, S. et al. Status of B-lymphocyte subsets and their homing markers in patients with post-kala-azar dermal leishmaniasis. Parasite Immunol. 46, e13031 (2024).
Moir, S. et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 116, 5571–5579 (2010).
Weiss, G. E. et al. Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J. Immunol. 183, 2176–2182 (2009).
Charles, E. D. et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood 117, 5425–5437 (2011).
Nylen, S. et al. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J. Exp. Med. 204, 805–817 (2007). This paper provides the first data supporting a role for IL-10 production by Tr1 cells in human visceral leishmaniasis.
Christensen, S. M. et al. Host and parasite responses in human diffuse cutaneous leishmaniasis caused by L. amazonensis. PLoS Negl. Trop. Dis. 13, e0007152 (2019).
Schiller, H. B. et al. Deep proteome profiling reveals common prevalence of MZB1-positive plasma B cells in human lung and skin fibrosis. Am. J. Respir. Crit. Care Med. 196, 1298–1310 (2017).
Swaminathan, S. et al. LAG-3- and CXCR5-expressing CD4 T cells display progenitor-like properties during chronic visceral leishmaniasis. Cell Rep. 43, 113879 (2024). This paper provides definitive evidence that progenitor-like LAG-3⁺CXCR5⁺CD4+ T cell subsets sustain and shape protective immunity during chronic infection.
Smelt, S. C., Engwerda, C. R., McCrossen, M. & Kaye, P. M. Destruction of follicular dendritic cells during chronic visceral leishmaniasis. J. Immunol. 158, 3813–3821 (1997).
Pioli, P. D. Plasma cells, the next generation: beyond antibody secretion. Front. Immunology 10, 2768 (2019).
Atnafu, A. et al. Histopathological patterns of cutaneous and mucocutaneous leishmaniasis due to L. aethiopica. Dermatol. Res. Pract. 2024, 5267606 (2024).
Cardozo, R. S., Garcia-Montero, P. P., Chicharro, C. & Tardio, J. C. Cutaneous leishmaniasis: a pathological study of 360 cases with special emphasis on the contribution of immunohistochemistry and polymerase chain reaction to diagnosis. J. Cutan. Pathol. 47, 1018–1025 (2020).
Thilakarathne, I. K., Ratnayake, P., Vithanage, A. & Sugathadasa, D. P. Role of histopathology in the diagnosis of cutaneous leishmaniasis: a case–control study in Sri Lanka. Am. J. Dermatopathol. 41, 566–570 (2019).
Ridley, D. S. The pathogenesis of cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 73, 150–160 (1979).
Ribeiro, C. S. et al. Cellular infiltrate in cutaneous leishmaniasis lesions and therapeutic outcome. An. Brasil. Dermatol. 96, 544–550 (2021).
Steier, Z., Kim, E. J. Y., Aylard, D. A. & Robey, E. A. The CD4 versus CD8 T cell fate decision: a multiomics-informed perspective. Annu. Rev. Immunol. 42, 235–258 (2024).
Sun, L., Su, Y., Jiao, A., Wang, X. & Zhang, B. T cells in health and disease. Signal. Transduct. Target. Ther. 8, 235 (2023).
da Silva Santos, C. & Brodskyn, C. I. The role of CD4 and CD8 T cells in human cutaneous leishmaniasis. Front. Public Health 2, 165 (2014).
Na, J. & Engwerda, C. The role of CD4+ T cells in visceral leishmaniasis; new and emerging roles for NKG7 and TGFβ. Front. Cell. Infect. Microbiol. 14, 1414493 (2024).
Scott, P. & Novais, F. O. Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat. Rev. Immunol. 16, 581–592 (2016).
Alexander, J. & Brombacher, F. T Helper1/T Helper2 cells and resistance/susceptibility to Leishmania infection: is this paradigm still relevant? Front. Immunol. 3, 80 (2012).
Gonçalves-de-Albuquerque, S. D. C. et al. The equivocal role of Th17 cells and neutrophils on immunopathogenesis of leishmaniasis. Front. Immunol. 8, 1437 (2017).
Hurrell, B. P., Regli, I. B. & Tacchini-Cottier, F. Different Leishmania species drive distinct neutrophil functions. Trends Parasitol. 32, 392–401 (2016).
Khattak, F. A. et al. Novel IL-12Rβ1 deficiency-mediates recurrent cutaneous leishmaniasis. Int. J. Infect. Dis. 112, 338–345 (2021).
Blackwell, J. M., Fakiola, M. & Castellucci, L. C. Human genetics of Leishmania infections. Hum. Genet. 139, 813–819 (2020). This is an excellent review of our understanding of the genetic control of human leishmaniasis.
Badaro, R. et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon γ. N. Engl. J. Med. 322, 16–21 (1990). This paper provides landmark clinical evidence that IFN-γ is a central mediator of parasite control in visceral leishmaniasis, demonstrating that adding IFN-γ to antimonial therapy greatly improves cure rates in patients.
Sundar, S. & Murray, H. W. Effect of treatment with interferon-γ alone in visceral leishmaniasis. J. Infect. Dis. 172, 1627–1629 (1995).
Sundar, S., Singh, V. P., Sharma, S., Makharia, M. K. & Murray, H. W. Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis. J. Infect. Dis. 176, 1117–1119 (1997). This paper provided clinical proof that IFN-γ is a critical effector of parasite control in visceral leishmaniasis by showing that adjunctive IFN-γ therapy markedly improves responses to antimonial treatment in patients with refractory disease.
Kumar, R. et al. Leishmania specific CD4 T cells release IFNγ that limits parasite replication in patients with visceral leishmaniasis. PLoS Negl. Trop. Dis. 8, e3198 (2014). This paper provides direct human evidence that IFN-γ produced by parasite-specific CD4⁺ T cells is a key effector of protection in visceral leishmaniasis by demonstrating that these cells limit Leishmania replication in patients.
Alimohammadian, M. H. et al. Assessment of interferon-γ levels and leishmanin skin test results in persons recovered for leishmaniasis. Am. J. Trop. Med. Hyg. 87, 70–75 (2012).
Giraldo-Parra, L. et al. Consolidation of a molecular signature of healing in cutaneous leishmaniasis is achieved during the first 10 days of treatment. J. Immunol. 212, 894–903 (2024).
Pacheco-Fernandez, T. et al. Revival of leishmanization and leishmanin. Front. Cell Infect. Microbiol. 11, 639801 (2021).
Schnorr, D. et al. IFN-γ production to Leishmania antigen supplements the Leishmania skin test in identifying exposure to L. braziliensis infection. PLoS Negl. Trop. Dis. 6, e1947 (2012).
Saldanha, M. G. et al. Tissue damage in human cutaneous leishmaniasis: correlations between inflammatory cells and molecule expression. Front. Cell Infect. Microbiol. 10, 355 (2020).
Tuzlak, S. et al. Repositioning TH cell polarization from single cytokines to complex help. Nat. Immunol. 22, 1210–1217 (2021).
Engwerda, C. R., Ng, S. S. & Bunn, P. T. The regulation of CD4+ T cell responses during protozoan infections. Front. Immunol. 5, 498 (2014).
Montes de Oca, M. et al. IL-27 signalling regulates glycolysis in Th1 cells to limit immunopathology during infection. PLoS Pathog. 16, e1008994 (2020).
Montes de Oca, M. et al. Blimp-1-dependent IL-10 production by Tr1 cells regulates TNF-mediated tissue pathology. PLoS Pathog. 12, e1005398 (2016). Revealed that CD4⁺ Tr1 cells are central regulators of disease outcome in visceral leishmaniasis by showing that Blimp-1-dependent IL-10 production restrains TNF-driven tissue pathology while shaping the balance between immunopathology and parasite control.
Ranatunga, D. et al. A human IL10 BAC transgene reveals tissue-specific control of IL-10 expression and alters disease outcome. Proc. Natl Acad. Sci. USA 106, 17123–17128 (2009).
Roncarolo, M. G., Gregori, S., Bacchetta, R., Battaglia, M. & Gagliani, N. The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases. Immunity 49, 1004–1019 (2018).
Costa, D. L. et al. Tr-1-like CD4+CD25−CD127−/lowFOXP3− cells are the main source of interleukin 10 in patients with cutaneous leishmaniasis due to Leishmania braziliensis. J. Infect. Dis. 211, 708–718 (2014).
Montes de Oca, M., Good, M. F., McCarthy, J. S. & Engwerda, C. R. The impact of established immunoregulatory networks on vaccine efficacy and the development of immunity to malaria. J. Immunol. 197, 4518–4526 (2016).
Bunn, P. T. et al. Distinct roles for CD4+Foxp3+ regulatory T cells and IL-10-mediated immunoregulatory mechanisms during experimental visceral leishmaniasis caused by Leishmania donovani. J. Immunol. 201, 3362–3372 (2018).
Ganguly, S. et al. Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis. J. Invest. Dermatol. 130, 1013–1022 (2010).
Katara, G. K., Ansari, N. A., Verma, S., Ramesh, V. & Salotra, P. Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients. PLoS Negl. Trop. Dis. 5, e1171 (2011).
Singh, S. S. et al. Increased amphiregulin expression by CD4+ T cells from individuals with asymptomatic Leishmania donovani infection. Clin. Transl. Immunol. 11, e1396 (2022).
Belkaid, Y. et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194, 1497–1506 (2001). This paper established that IL-10-producing CD4⁺ T cells are key regulators of parasite persistence in leishmaniasis, revealing that CD4⁺ T-cell-derived immunoregulation can permit chronic infection and that targeting this pathway can enable sterile cure.
Belkaid, Y., Piccirillo, C. A., Mendez, S., Shevach, E. M. & Sacks, D. L. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420, 502–507 (2002). This paper provides seminal evidence that CD4⁺ T cells are pivotal determinants of disease outcome in leishmaniasis by showing that CD4⁺ CD25⁺ regulatory T cells actively control parasite persistence and the balance between protective immunity and chronic infection.
Zayats, R. et al. Antigen recognition reinforces regulatory T cell mediated Leishmania major persistence. Nat. Commun. 14, 8449 (2023).
Yurchenko, E. et al. CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J. Exp. Med. 203, 2451–2460 (2006).
Elizondo, G., Rodríguez-Sosa, M., Estrada-Muñiz, E., Gonzalez, F. J. & Vega, L. Deletion of the aryl hydrocarbon receptor enhances the inflammatory response to Leishmania major infection. Int. J. Biol. Sci. 7, 1220–1229 (2011).
Sacks, D. & Noben-Trauth, N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol 2, 845–858 (2002).
Silva-Freitas, M. L., Corrêa-Castro, G., Da-Cruz, A. M. & Santos-Oliveira, J. R. Insights to the HIV-associated visceral leishmaniasis clinical outcome: lessons learned about immune mediated disorders. Front. Immunol. 16, 2025 (2025).
Takele, Y. et al. Recurrent visceral leishmaniasis relapses in HIV co-infected patients are characterized by less efficient immune responses and higher parasite load. iScience 26, 105867 (2023).
Künzli, M. & Masopust, D. CD4+ T cell memory. Nat. Immunol. 24, 903–914 (2023).
Kaech, S. M., Wherry, E. J. & Ahmed, R. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2, 251–262 (2002).
Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745–763 (2004).
Szabo, P. A., Miron, M. & Farber, D. L. Location, location, location: tissue resident memory T cells in mice and humans. Sci. Immunol. 4, eaas9673 (2019).
Zaph, C., Uzonna, J., Beverley, S. M. & Scott, P. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10, 1104–1110 (2004). This paper provided proof that CD4⁺ T cells underpin durable protection in cutaneous leishmaniasis by showing that central memory CD4⁺ T cells can sustain long-term immunity to Leishmania major even in the absence of persistent parasites.
Masopust, D. et al. Guidelines for T cell nomenclature. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-025-01238-2 (2025).
Schnell, A. et al. Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunity. Cell 184, 6281–6298.e6223 (2021).
Xia, Y. et al. BCL6-dependent TCF-1+ progenitor cells maintain effector and helper CD4+ T cell responses to persistent antigen. Immunity 55, 1200–1215.e1206 (2022).
Zou, D. et al. CD4+ T cell immunity is dependent on an intrinsic stem-like program. Nat. Immunol. 25, 66–76 (2024).
Gattinoni, L. et al. A human memory T cell subset with stem cell–like properties. Nat. Med. 17, 1290–1297 (2011).
Watanabe, R. et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci. Transl. Med. 7, 279ra239 (2015).
Glennie, N. D. et al. Skin-resident memory CD4+ T cells enhance protection against Leishmania major infection. J. Exp. Med. 212, 1405–1414 (2015). This paper established that CD4⁺ T cells are key mediators of frontline protection in cutaneous leishmaniasis by demonstrating that skin-resident memory CD4⁺ T cells provide rapid, local immunity against Leishmania major reinfection.
Glennie, N. D., Volk, S. W. & Scott, P. Skin-resident CD4+ T cells protect against Leishmania major by recruiting and activating inflammatory monocytes. PLoS Pathog. 13, e1006349 (2017).
Scott, P. Long-lived skin-resident memory T cells contribute to concomitant immunity in cutaneous leishmaniasis. Cold Spring Harb. Persp. Biol. 12, a038059 (2020).
Ismail, N. et al. Leishmania major centrin gene-deleted parasites generate skin resident memory T-cell immune response analogous to leishmanization. Front. Immunol. 13, 864031 (2022).
Fowler, E. A. & Novais, F. O. Step-by-step: the CD8 T cell journey in leishmaniasis. mBio 16, e03537–03523 (2025). This is a contemporary in-depth review of the role of CD8+ T cells in immunity and pathology.
Stager, S. & Rafati, S. CD8+ T cells in Leishmania infections: friends or foes? Front. Immunol. 3, 5 (2012).
Gautam, S. et al. CD8 T cell exhaustion in human visceral leishmaniasis. J. Infect. Dis. 209, 290–299 (2014).
Ademe, M. et al. T-cell and soluble co-inhibitory receptor expression in patients with visceral leishmaniasis are markers of treatment response and clinical outcome. Open Forum Infect. Dis. 11, ofae649 (2024).
Singh, B. et al. A molecular signature for CD8+ T cells from visceral leishmaniasis patients. Parasite Immunol. 41, e12669 (2019).
de Franca, M. N. F. et al. CD4+ Th1 and Th17 responses and multifunctional CD8 T lymphocytes associated with cure or disease worsening in human visceral leishmaniasis. Front. Immunol. 15, 1277557 (2024).
Rodrigues, L. S. et al. Multifunctional, TNF-α and IFN-γ-secreting CD4 and CD8 T cells and CD8High T cells are associated with the cure of human visceral leishmaniasis. Front. Immunol. 12, 773983 (2021).
Kaushal, H. et al. Role of CD8+ T cells in protection against Leishmania donovani infection in healed visceral leishmaniasis individuals. BMC Infect. Dis. 14, 653 (2014).
Mastrolia, M. V. et al. CD38high/HLA-DR+CD8+ T cells as potential biomarker of hemophagocytic lymphohistiocytosis secondary to visceral Leishmania infection. Eur. J. Pediat. 182, 1429–1432 (2023).
Mukherjee, S. et al. Impaired activation of lesional CD8+ T-cells is associated with enhanced expression of programmed death-1 in Indian post kala-azar dermal leishmaniasis. Sci. Rep. 9, 762 (2019).
Novais, F. O. & Scott, P. CD8+ T cells in cutaneous leishmaniasis: the good, the bad, and the ugly. Semin. Immunopathol. 37, 251–259 (2015).
Sacramento, L. A. et al. NKG2D promotes CD8 T cell-mediated cytotoxicity and is associated with treatment failure in human cutaneous leishmaniasis. PLoS Negl. Trop. Dis. 17, e0011552 (2023).
Amorim, C. F. et al. Variable gene expression and parasite load predict treatment outcome in cutaneous leishmaniasis. Sci. Transl. Med. 11, eaax4204 (2019).
Cardoso, T. M. et al. Inflammasome activation by CD8+ T cells from patients with cutaneous leishmaniasis caused by Leishmania braziliensis in the immunopathogenesis of the disease. J. Invest. Dermatol. 141, 209–213 e202 (2021).
Novais, F. O. et al. CD8+ T cell cytotoxicity mediates pathology in the skin by inflammasome activation and IL-1β production. PLoS Pathog. 13, e1006196 (2017). This paper provides decisive evidence that CD8⁺ T cells can drive disease pathology in cutaneous leishmaniasis by showing that cytotoxic CD8⁺ T cell activity promotes inflammasome activation and IL-1β-dependent tissue damage in the skin.
Fowler, E. A. et al. Neutrophil-mediated hypoxia drives pathogenic CD8+ T cell responses in cutaneous leishmaniasis. J. Clin. Invest. 134, e177992 (2024). This paper provides an important link between tissue microenvironment and control of cytolytic activity of CD8+ T cells.
Abreu, C. A. et al. The role of senescent CD8+ T cells in the pathogenesis of disseminated leishmaniasis. Pathogens 13, e177992 (2024).
Covre, L. P., De Maeyer, R. P. H., Gomes, D. C. O. & Akbar, A. N. The role of senescent T cells in immunopathology. Aging Cell 19, e13272 (2020).
Fantecelle, C. H. et al. Senescence-related genes are associated with the immunopathology signature of American tegumentary leishmaniasis lesions and may predict progression to mucosal leishmaniasis. Clin. Exp. Immunol. 219, uxae088 (2025).
Covre, L. P. et al. Compartmentalized cytotoxic immune response leads to distinct pathogenic roles of natural killer and senescent CD8+ T cells in human cutaneous leishmaniasis. Immunology 159, 429–440 (2020).
Dey, N. S. et al. IL-32 producing CD8+ memory T cells and Tregs define the IDO1/PD-L1 niche in human cutaneous leishmaniasis skin lesions. J. Clin. Invest. 135, e182040 (2025). This paper describes the first use of spatial transcriptomics to identify upstream regulators of immune checkpoint molecule expression.
Dey, N. S. et al. Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis. J. Clin. Invest. 131, e142765 (2021). This paper describes the first application of spatial transcriptomics, showing that treatment outcome is regulated by immune checkpoint molecules.
Parkash, V. et al. Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis. Nat. Med. 30, 3150–3162 (2024). This paper describes a new translational model for evaluating Leishmania vaccine candidates and host-directed interventions, and molecular characterization of early lesion development.
Clarencio, J. et al. Characterization of the T-cell receptor Vβ repertoire in the human immune response against Leishmania parasites. Infect. Immun. 74, 4757–4765 (2006).
Kariminia, A. et al. Selective expression of the Vβ 14T cell receptor on Leishmania-specific CD8+ T cells during human infection. J. Infect. Dis. 195, 739–747 (2007).
Uyemura, K. et al. CD4+ type 1 and CD8+ type 2T cell subsets in human leishmaniasis have distinct T cell receptor repertoires. J. Immunol. 151, 7095–7104 (1993).
Bahrami, F. et al. Blood transcriptional profiles distinguish different clinical stages of cutaneous leishmaniasis in humans. Mol. Immunol. 149, 165–173 (2022).
Farias Amorim, C. et al. Multiomic profiling of cutaneous leishmaniasis infections reveals microbiota-driven mechanisms underlying disease severity. Sci. Transl. Med. 15, eadh1469 (2023). This paper provides a key link between microbiota and outcome in cutaneous leishmaniasis.
Gardinassi, L. G., Garcia, G. R., Costa, C. H., Costa Silva, V. & de Miranda Santos, I. K. Blood transcriptional profiling reveals immunological signatures of distinct states of infection of humans with Leishmania infantum. PLoS Negl. Trop. Dis. 10, e0005123 (2016).
Masoudzadeh, N., Mizbani, A. & Rafati, S. Transcriptomic profiling in cutaneous leishmaniasis patients. Expert. Rev. Proteom. 17, 533–541 (2020).
Mohebali, M., Nadim, A. & Khamesipour, A. An overview of leishmanization experience: a successful control measure and a tool to evaluate candidate vaccines. Acta Trop. 200, 105173 (2019).
Kaye, P. M. et al. Vaccine value profile for leishmaniasis. Vaccine 41, S153–S175 (2023). This paper provides essential immunological, epidemiological, social and economic background to support investment in vaccine development for leishmaniasis.
Volpedo, G. et al. The history of live attenuated centrin gene-deleted Leishmania vaccine candidates. Pathogens 11, 431 (2022).
Osman, M. et al. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl. Trop. Dis. 11, e0005527 (2017).
Duthie, M. S., Machado, B. A. S., Badaró, R., Kaye, P. M. & Reed, S. G. Leishmaniasis vaccines: applications of RNA technology and targeted clinical trial designs. Pathogens 11, 1259 (2022).
Mou, Z. et al. Identification of broadly conserved cross-species protective Leishmania antigen and its responding CD4+ T cells. Sci. Transl. Med. 7, 310ra167 (2015). This paper describes a major methodological and conceptual advance for dissecting CD4⁺ T cell immunity in leishmaniasis by identifying a conserved, cross-species protective Leishmania antigen and the antigen-specific CD4⁺ T cells that respond to it, enabling precise tracking and functional analysis of protective T cell responses.
Barazandeh, A. F. et al. The phosphoenolpyruvate carboxykinase is a key metabolic enzyme and critical virulence factor of Leishmania major. J. Immunol. 206, 1013–1026 (2021).
Adriaensen, W. et al. Breaking the deadlock in antigen discovery for Leishmania vaccines. Trends Parasitol. 42, 183–191 (2026).
Carroll, S. L., Pasare, C. & Barton, G. M. Control of adaptive immunity by pattern recognition receptors. Immunity 57, 632–648 (2024).
Kumar, R., Chauhan, S. B., Ng, S. S., Sundar, S. & Engwerda, C. R. Immune checkpoint targets for host-directed therapy to prevent and treat leishmaniasis. Front. Immunol. 8, 1492 (2017).
Novais, F. O., Nguyen, B. T. & Scott, P. Granzyme B inhibition by tofacitinib blocks the pathology induced by CD8 T cells in cutaneous leishmaniasis. J. Invest. Dermatol. 141, 575–585 (2021).
de Vrij, N. et al. Persistent T cell unresponsiveness associated with chronic visceral leishmaniasis in HIV-coinfected patients. Commun. Biol. 7, 524 (2024). This was the first study to define T cell response in people with both HIV and visceral leishmaniasis at single-cell and clonal resolution.
Benotmane, J. K. et al. High-sensitive spatially resolved T cell receptor sequencing with SPTCR-seq. Nat. Commun. 14, 7432 (2023).
Yazdanbakhsh, M. & Sacks, D. L. Why does immunity to parasites take so long to develop? Nat. Rev. Immunol. 10, 80–81 (2010).
Akuffo, H. et al. Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin-10 while those from localized leishmaniasis patients induce interferon-γ. J. Infect. Dis. 175, 737–741 (1997).
Brodskyn, C. I., Barral, A., Boaventura, V., Carvalho, E. & Barral-Netto, M. Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis. J. Immunol. 159, 4467–4473 (1997).
Singh, O. P. et al. Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. Lancet Microbe 2, e23–e31 (2021). This paper provides definitive, real-world evidence for transmission from humans to sand flies in visceral leishmaniasis by using xenodiagnosis to directly quantify the infectiousness of humans to sandflies, reshaping how transmission dynamics and control strategies are understood.
Ronsmans, S. et al. The EXIMIOUS project-mapping exposure-induced immune effects: connecting the exposome and the immunome. Environ. Epidemiol. 6, e193 (2022). This paper provides a road map and toolbox for studying exposome factors that could be applied in longitudinal cohort studies of leishmaniasis.
Belkaid, Y. & Tamoutounour, S. The influence of skin microorganisms on cutaneous immunity. Nat. Rev. Immunol. 16, 353–366 (2016).
Brown, S. P. & Grenfell, B. T. An unlikely partnership: parasites, concomitant immunity and host defence. Proc. Biol. Sci. 268, 2543–2549 (2001).
Southgate, B. A. & Manson-Bahr, P. E. Studies in the epidemiology of East African leishmaniasis. 4. The significance of the positive leishmanin test. J. Trop. Med. Hyg. 70, 29–33 (1967).
Stanley, A. C. & Engwerda, C. R. Balancing immunity and pathology in visceral leishmaniasis. Immunol. Cell Biol. 85, 138–147 (2007).
Osum, K. C. & Jenkins, M. K. Toward a general model of CD4+ T cell subset specification and memory cell formation. Immunity 56, 475–484 (2023).
Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83–100 (2021).
van Dorst, M. et al. Immunological factors linked to geographical variation in vaccine responses. Nat. Rev. Immunol. 24, 250–263 (2024).
Bekker, L. G. et al. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet 395, 384–388 (2020).
Hatherill, M., White, R. G. & Hawn, T. R. Clinical development of new TB vaccines: recent advances and next steps. Front. Microbiol. 10, 3154 (2019).
Singh, O. P., Hasker, E., Boelaert, M. & Sundar, S. Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect. Dis. 16, e304–e309 (2016).
Sacks, D. L. Vaccines against tropical parasitic diseases: a persisting answer to a persisting problem. Nat. Immunol. 15, 403–405 (2014).
Moguche, A. O. et al. ICOS and Bcl6-dependent pathways maintain a CD4 T cell population with memory-like properties during tuberculosis. J. Exp. Med. 212, 715–728 (2015).
Kratchmarov, R. et al. TCF1-LEF1 co-expression identifies a multipotent progenitor cell (T(H)2-MPP) across human allergic diseases. Nat. Immunol. 25, 902–915 (2024).
Shin, B. et al. Effector CD4 T cells with progenitor potential mediate chronic intestinal inflammation. J. Exp. Med. 215, 1803–1812 (2018).
Pepper, M., Pagan, A. J., Igyarto, B. Z., Taylor, J. J. & Jenkins, M. K. Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells. Immunity 35, 583–595 (2011).
Mou, Z. et al. Persistent antigen is essential for sustaining Leishmania major-specific memory CD4+ T cells and long-term immunity. Sci. Adv. 12, eaeb3345 (2026).
